Background: The adaptive immune response is a crucial component of the protective immunity against SARS-CoV-2, generated after infection or vaccination. Methods: We studied antibody titers, neutralizing antibodies and cellular immune responses to four different COVID-19 vaccines, namely Pfizer-BioNTech, Moderna Spikevax, AstraZeneca and Sinopharm vaccines in the Bangladeshi population (n = 1780). Results: mRNA vaccines Moderna (14,655 ± 11.3) and Pfizer (13,772 ± 11.5) elicited significantly higher anti-Spike (S) antibody titers compared to the Adenovector vaccine AstraZeneca (2443 ± 12.8) and inactivated vaccine Sinopharm (1150 ± 11.2). SARS-CoV-2-specific neutralizing antibodies as well as IFN-γ-secreting lymphocytes were more abundant in Pfizer and Moderna vaccine recipients compared to AstraZeneca and Sinopharm vaccine recipients. Participants previously infected with SARS-CoV-2 exhibited higher post-vaccine immune responses (S-specific and neutralizing antibodies, IFN-γ-secreting cells) compared to uninfected participants. Memory B (BMEM), total CD8+T, CD4+ central memory (CD4+CM) and T-regulatory (TREG) cells were more numerous in AstraZeneca vaccine recipients compared to other vaccine recipients. Plasmablasts, B-regulatory (BREG) and CD4+ effector (CD4+EFF) cells were more numerous in mRNA vaccine recipients. Conclusions: mRNA vaccines generated a higher antibody response, while a differential cellular response was observed for different vaccine types, suggesting that both cellular and humoral responses are important in immune monitoring of different types of vaccines.
Anaemia during pregnancy poses a major public health problem globally, with reported prevalences ranging from approximately 5.2% to 65.7%. A significant portion of this burden is borne by low- and middle-income countries. We aimed to determine the prevalence of anaemia during pregnancy and identify the factors associated with anaemia in the third trimester of pregnancy in a cohort of women in the rural Sylhet district, Bangladesh. We enrolled 3000 pregnant women between 8 and 19 weeks of gestational age (GA). Trained community health workers collected data on their sociodemographic, obstetric, nutritional, dietary, anthropometric, and household characteristics. Blood samples were collected at baseline (<20 weeks of gestation) and at a follow-up visit between 24-36 weeks of GA to measure haemoglobin (Hb) concentrations. We classified them according to their anaemia status into no anaemia (Hb ≥11g/dl), mild (10 to <11 g/dl), and moderate to severe (<10g/dl) groups. We then used unadjusted and adjusted multinomial logistic regression models to calculate the relative risk ratios (RRR) and 95% confidence intervals (CIs) of potential risk factors for mild or moderate to severe anaemia in the third trimester of pregnancy. Of the 2679 women tested at enrolment, 1010 (38%) were anaemic, 634 (24%) had mild anaemia, and 376 (14%) had moderate to severe anaemia. At the third-trimester follow-up, 1950 (79%) of 2473 women were anaemic; 739 (30%) had mild anaemia, and 1211 (49%) had moderate to severe anaemia. Women with baseline mild anaemia had about a five-fold higher risk (RRR = 4.84; 95% CI = 3.64-6.46) and those with moderate to severe anaemia about an 11-fold higher risk (RRR = 10.78; 95% CI = 6.69-17.35) of having moderate to severe anaemia in the third trimester. Iron supplementation during pregnancy (RRR = 0.75; 95% CI = 0.60-0.93) and drinking tubewell water (RRR = 0.76; 95% CI = 0.60-0.96) were significantly associated with a lower risk of moderate to severe anaemia in the third trimester. We documented a high rate of anaemia in our sample, particularly during the third trimester of pregnancy, underscoring an urgent need for interventions to improve maternal and child health outcomes, such as improved nutrition education, expanded access to and adherence with iron supplementation, and enhanced antenatal care.